Recursion Pharmaceuticals (RXRX) Total Debt (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Total Debt came in at $16.4 million in Q1 2026, down 34.3% YoY from $25.0 million in Q1 2025, and down 11.84% on a QoQ basis from $18.7 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Total Debt (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Total Debt data on file, last reported at $16.4 million in Q1 2026.
- Quarterly Total Debt fell 34.3% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.4 million (down 34.3% YoY) and the FY2025 annual result came in at $18.7 million, down 32.03% from the prior year.
- Total Debt slipped to $16.4 million in Q1 2026, from $18.7 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $31.0 million in Q2 2024 to a low of $536000.0 in Q4 2022.
- A 5-year average of $12.4 million and a median of $8.8 million in 2023 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2022 — Total Debt sank 93.78% — and 2024, when it surged 2586.58%.
- Tracing RXRX's Total Debt over 5 years: stood at $536000.0 in 2022, then soared by 113.06% to $1.1 million in 2023, then jumped by 2303.42% to $27.4 million in 2024, then tumbled by 32.03% to $18.7 million in 2025, then decreased by 11.84% to $16.4 million in 2026.
- The last three Total Debt figures came in at $16.4 million (Q1 2026), $18.7 million (Q4 2025), and $20.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 14.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.20 Mn |
| Mar 31, 2026 | 16.45 Mn |
| Dec 31, 2025 | 18.66 Mn |
| Sep 30, 2025 | 20.82 Mn |
| Jun 30, 2025 | 22.95 Mn |
| Mar 31, 2025 | 25.03 Mn |
| Dec 31, 2024 | 27.45 Mn |
| Sep 30, 2024 | 28.73 Mn |
| Jun 30, 2024 | 31.03 Mn |
| Mar 31, 2024 | 1.07 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.13 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 536,000.00 |
| Jun 30, 2022 | 586,000.00 |
| Mar 31, 2022 | 610,000.00 |
| Dec 31, 2021 | 633,000.00 |
| Sep 30, 2021 | 3.46 Mn |
| Jun 30, 2021 | 9.42 Mn |